Specific Biologics Closes 35 Million Dollar Series A
Specific Biologics announced November 2 the close of an oversubscribed US$35 million Series A led by Hatteras Venture Partners. It plans to fund its C9ORF72 repeat-expansion editing candidate through initial biomarker proof of concept…
